特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
915072

癌治療薬の薬価・償還・市場アクセス (2019-2029年):主要国別

Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China

出版日: | 発行: Visiongain Ltd | ページ情報: 英文 292 Pages | 納期: 即日から翌営業日

価格
価格表記: GBPを日本円(税抜)に換算
本日の銀行送金レート: 1GBP=143.04円

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

癌治療薬の薬価・償還・市場アクセス (2019-2029年):主要国別
出版日: 2019年09月10日
発行: Visiongain Ltd
ページ情報: 英文 292 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界の癌治療薬の薬価・償還・市場アクセスの動向を調査し、癌および癌治療薬の概要、主な癌治療薬、パイプラインの動向、薬価設定・償還制度におけるHEOR・HTAの重要性、主要国別の医療制度、薬価設定・償還プロセス、癌治療薬のコスト、保険者に関する分析などをまとめています。

第1章 レポート概要

第2章 市場概要

  • 癌と治療:過去の経緯
  • 治療と予防

第3章 世界の薬価・償還

  • 薬価・償還決定への影響因子
  • 薬価の交渉・値下げ
  • 新薬の薬価
  • 償還政策

第4章 経済評価

  • HEORの役割および経済価値プランニング
  • 費用対効果分析の概要
  • 治療薬の特許満了・薬価への影響

第5章 市場アクセスにおける医療技術評価 (HTA)

  • HTAとそのプロセスの主なメリット
  • 主なHTA規制当局
  • ケーススタディ:英国NICEについての概略

第6章 市場分析:主要国別

  • 米国
  • カナダ
  • 欧州 (EU5カ国)
  • アジア太平洋
  • BRIC諸国
    • 医療制度
    • 薬価設定・償還プロセス
    • 癌治療薬のコスト
    • 保険者に関する分析
    • 国内市場の特徴

第7章 並行輸入とその影響

  • 欧州における並行輸入
  • 米国における並行輸入
  • 並行貿易における経済的側面
図表

List of Table

  • Table 2.1: Top 10 Best-selling Oncology Drugs, 2018
  • Table 2.2: Pipeline Treatments Drugs for Oncology
  • Table 5.1: Institutions and advisory bodies responsible for HTA activities in EU
  • Table 6.1: The U.S.: Average ASP for Top Biologic Oncology Drugs
  • Table 6.2: Cost of Treatment in the U.S. for Oncology drugs (AWP Prices) (USD)
  • Table 6.3: Key Reimbursement Stakeholders' in Canada
  • Table 6.4: Canada- Oncology Drug Price - Unit Ex-Factory Prices ($CAD)
  • Table 6.5: Canada- Oncology Cost of Treatment ($CAD)
  • Table 6.6: U.K.: Oncology Drugs Price, 2016-2019 - Unit Ex-Factory Prices (GBP)
  • Table 6.7: U.K.: Oncology Cost of Treatment (2016-2019)
  • Table 6.8: Germany Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (Euro) (2016-2019)
  • Table 6.9: Germany: Oncology Annual Treatment Cost, 2016-2019
  • Table 6.10: France: Oncology Cost of Treatment
  • Table 6.11: Italy Competitor Pricing of Onology Drugs - Unit Ex-factory Prices (€) (2016-2019)
  • Table 6.12: Italy: Oncology Cost of Treatment
  • Table 6.13: Spain Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (EUR) 2016-2019
  • Table 6.14: Spain: Oncology Annual Treatment Cost, 2016-2019
  • Table 6.15: Japan: Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (¥) (2016-2019)
  • Table 6.16: Australia Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (AUD) (2016-2019)
  • Table 6.17: Brazil Competitor Pricing of Oncology Drugs - Per Pack Ex-factory Prices (BRL) (2016-2019)
  • Table 6.18: Russia Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (RUB) (2016-2019)
  • Table 6.19: India Competitor Pricing of Rheumatoid Arthritis Drugs - Unit Ex-factory Prices (INR) (2016-2019)
  • Table 6.20: China Competitor Pricing of Oncology Drugs - Unit Ex-factory Prices (CNY) (2016-2019)

List of Figure

  • Figure 2.1: Estimated Number of New Cases Worldwide in 2018
  • Figure 5.1: Aspects of HTA for Different Technologies and Interventions
  • Figure 6.1: U.S.: Key Organisations in the US Healthcare System
  • Figure 6.2: The U.S. - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.3: The U.S. - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.4: The U.S.: Market Access Flow in United States
  • Figure 6.5: The U.S.: Federally Funded Health Insurance Plans
  • Figure 6.6: The U.S.: Top Oncology Drugs Price Trend in U.S. (AWP in USD) (2016-2019)
  • Figure 6.7: Canada - Healthcare Structure
  • Figure 6.8: Canada - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.9: Canada - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.10: Pricing & Reimbursement in Canada
  • Figure 6.11: Pathways to Reimbursement in Canada
  • Figure 6.12: Top Oncology Drugs Price Trend in Canada
  • Figure 6.13: Canada- Breast Cancer Guideline Pathway
  • Figure 6.14: U.K. - Healthcare System Structure
  • Figure 6.15: U.K. - National Expenditures (as of % GDP Spending), 2013-2015
  • Figure 6.16: Pricing & Reimbursement in the U.K.
  • Figure 6.17: Health Technology Assessment & Appraisal in the U.K.
  • Figure 6.18: U.K.: Oncology Drugs Price Trend (GBP), 2016-2019
  • Figure 6.19: Germany - Healthcare System Structure
  • Figure 6.20: Key Decision-makers in German Healthcare System
  • Figure 6.21: Germany - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.22: Germany - Multi-player nature of German Healthcare System
  • Figure 6.23: Pricing & Reimbursement in Germany
  • Figure 6.24: Germany Health Technology Assessment
  • Figure 6.25: Germany: Oncology - Top Drugs Price Trend - Unit List Price, EUR (2016-2019)
  • Figure 6.26: France Healthcare System Structure
  • Figure 6.27: France - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.28: France - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.29: Pricing & Reimbursement in France
  • Figure 6.30: Health Technology Assessment in France
  • Figure 6.31: France: Drug Review & Decision Process:
  • Figure 6.32: Oncology Drugs Price Trend, (EUR) 2016-2019
  • Figure 6.33: Italy Healthcare System Structure
  • Figure 6.34: Italy - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.35: Italy - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.36: Pricing & Reimbursement in Italy
  • Figure 6.37: Oncology Drugs Price Trend in Italy, 2016-2019 (EUR)
  • Figure 6.38: Spain - Healthcare System Structure
  • Figure 6.39: Spain - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.40: Spain - National Expenditures (% of GDP Spending), 2016
  • Figure 6.41: Pricing & Reimbursement in Spain
  • Figure 6.42: Reimbursement of pharmaceuticals in Spain
  • Figure 6.43: Health Technology Assessment in Spain
  • Figure 6.44: Spain: Top Oncology Drugs Price Trend, 2016-2019 (EUR)
  • Top Anti-TNF Drugs Price Trend - Spain
  • Figure 6.45: Japan - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.46: Japan - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.47: Japan Healthcare System Structure
  • Figure 6.48: Health Technology Assessment in Japan
  • Figure 6.49: Oncology Drugs Price Trend in Japan
  • Figure 6.50: Australia - Healthcare System Structure
  • Figure 6.51: Australia - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.52: Health Technology Assessment & Regulatory and Approval Process in Australia
  • Figure 6.53: Australia: Oncology Drugs Price Trend
  • Figure 6.54: Brazil - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.55: Key Decision-Makers in Brazilian Healthcare System
  • Figure 6.56: Brazil: ANVISA's Regulatory Approval Pathway For Biological Products
  • Figure 6.57: Brazil: Top Oncology Drug Price Trend (2016-2019)
  • Figure 6.58: Russia Healthcare System Structure
  • Figure 6.59: Russia - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.60: Russia - National Expenditures (as of %GDP Spending), 2016
  • Figure 6.61: Oncology Drugs Price Trend in Russia
  • Figure 6.62: India - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.63: India Healthcare System Structure Figure 6.62: India - Healthcare Expenditure (% of GDP Spending), 2014-2017
  • Figure 6.64: Key Decision-Makers in Indian Healthcare System
  • Figure 6.65: Oncology Drugs Price Trend in India (2016-2019)
  • Figure 6.66: China: Healthcare System Structure
  • Figure 6.67: China - Healthcare Expenditure (% of GDP Spending), 2013-2016
  • Figure 6.68: China - National Expenditures (as of % GDP Spending), 2016
  • Figure 6.69: Pricing & Reimbursement in China
  • Figure 6.70: China: Health Technology Assessment
  • Figure 6.71: Oncology Drugs Price Trend in China

List of Leading Companies Mentioned in the Report

  • AbbVie
  • Amgen
  • Biogen
  • BMJ Group
  • Bristol-Myers Squib
  • Canadian Life and Health Insurance Association, Inc.
  • Celgene
  • Genentech
  • Great West Life
  • Helpucover Health Insurance
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Merck & Co.
  • National Friendly HealthCare
  • Ono Pharmaceutical, Co.
  • Pfizer
  • PruHealth
  • Roche
  • Saga Health Insurance
  • Simply Health

List of Organizations Mentioned in the Report:

  • Agency for Healthcare Research and Quality
  • American Cancer Society
  • Centre for Disease Control and Prevention
  • Centre for Medicare and Medicaid Services
  • Department of Health Medicines, Pharmacy and Industry Group
  • Economic Committee for Medical Products
  • European Medicines Agency
  • Food and Drug Administration
  • German Cancer Research Centre
  • German Federal Ministry of Health
  • German Medical Association
  • International Agency for Research on Cancer
  • Medicines and Healthcare products Regulatory Agency
  • National Agency for the Safety of Medicines and Health Products
  • National Association of Statutory Health Insurance Physicians
  • National Health Authority
  • National Institute for Clinical Excellence
  • National Institute for Health and Clinical Excellence
  • National Institute for Health Research
  • National Institutes of Health
  • The Christie Hospital in Manchester
  • University College London Hospital
  • WHO
目次
Product Code: PHA0522

The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.

In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer's perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.

How this report will benefit you:

In this brand new 292-page report you will receive 98 charts - all unavailable elsewhere.

The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Key questions answered by this report:

  • Factors Affecting Pricing and Reimbursement Decision
  • Pricing Negotiations and Discounts
  • Reimbursement Policies
  • Role of HEOR and Economic Value Planning
  • Drug Patent Expiry and Effects on Pricing
  • Cost-Effectiveness Analysis

This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:

  • United States
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Japan
  • Australia
  • Brazil
  • Russia
  • India
  • China
  • Discussion on parallel import and its impact in the US and Europe.

Visiongain's study is intended for anyone requiring commercial analyses for the Global Oncology Pricing, Reimbursement and Market Access. You find data, trends and predictions.

Buy our report today Global Oncology Pricing, Reimbursement & Market Access 2019-2029: US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Benefits of This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report
  • 1.4 Who is This Report For?
  • 1.5 Methods of the Study
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2. Market Overview

  • 2.1. A Brief History of Oncology and Treatments
  • 2.2. Oncology: Treatment and Prevention

3. Global Pricing & Reimbursement of Therapeutic Drugs

  • 3.1 Factors Affecting Pricing & Reimbursement Decision
  • 3.2 Price Negotiations & Discounts
  • 3.3 Pricing of a New Drug
  • 3.4 Reimbursement Policies

4. Economic Evaluations

  • 4.1 Role of HEOR and Economic Value Planning
  • 4.2 Overview of Cost-Effectiveness Analysis
  • 4.3 Drug Patent Expiry & Effects on Pricing

5. Health Technology Assessment (HTA) in Market Access

  • 5.1 Key Benefits of HTA and its Process
  • 5.2 Principle HTA Regulatory Agencies
  • 5.3 Case Study: Brief About United Kingdom's NICE

6. Global Pharmaceuticals Market Dynamics

  • 6.1. United States (U.S.)
    • 6.1.1. U.S. Healthcare System
      • 6.1.1.1. Healthcare Expenditure
      • 6.1.1.2. Key Formularies
      • 6.1.1.3. Role of Pharmacists in the U.S. Healthcare System
      • 6.1.1.4. Regulatory and Approval Process
    • 6.1.2. Pricing & Reimbursement Process and HTA
    • 6.1.3. Oncology Cost of Treatment in The United States
    • 6.1.4. United States' Payer Insights
    • 6.1.5. Features of Oncology in the United States
  • 6.2 Canada
    • 6.2.1. Canada Healthcare System
      • 6.2.1.1. Healthcare Expenditure
      • 6.2.1.2. Health Coverage
      • 6.2.1.3. Key Formularies
      • 6.2.1.4. Role of Pharmacists in Canada Healthcare System
    • 6.2.2 Pricing & Reimbursement
      • 6.2.2.1. Pricing of Pharmaceuticals in Canada
      • 6.2.2.2 Reimbursement in Canada
    • 6.2.3 Health Technology Assessment
    • 6.2.4 Oncology Cost of Treatment
    • 6.2.5 Canada Payer Insight
    • 6.2.6 Features of Canadian Healthcare for Oncology
  • 6.3. Europe (EU5)
    • 6.3.1 United Kingdom
      • 6.3.1.1 United Kingdom Healthcare System
        • 6.3.1.1.1. Healthcare Expenditure
        • 6.3.1.1.2. Health Coverage
        • 6.2.1.1.3. Key Formularies
        • 6.2.1.1.4. Role of Pharmacists in the U.K. Healthcare System
      • 6.3.1.2. Pricing & Reimbursement
        • 6.3.1.2.1. Pricing of Pharmaceuticals in the U.K.
        • 6.3.1.2.2. Reimbursement of Pharmaceuticals in the U.K.
      • 6.3.1.3. Health Technology Assessment
      • 6.3.1.4. Cost of Oncology in the United Kingdom
      • 6.3.1.5. U.K. Payer Insight
      • 6.3.1.6. Features of Oncology in the U.K.
    • 6.3.2 Germany
      • 6.3.2.1 Germany Healthcare System
      • 6.3.2.2 Key Organisations in German Healthcare System
      • 6.3.2.3. Healthcare Expenditure
      • 6.3.2.4. Health Coverage
      • 6.3.2.5. Key Formularies
      • 6.3.2.6. Role of Pharmacists in German Healthcare System
      • 6.3.2.7. Pricing & Reimbursement
      • 6.3.2.8. Health Technology Assessment
      • 6.3.2.9 Regulatory & Approval Process
      • 6.3.2.10. Oncology Cost of Treatment in Germany
      • 6.3.2.11. Germany's Payer Insights
      • 6.3.2.12. Features of RA in Germany
    • 6.3.3 France
      • 6.3.3.1. France Healthcare System
        • 6.3.3.1.1. Healthcare Expenditure
        • 6.3.3.1.2. Health Coverage
        • 6.3.3.1.3. Key formularies
        • 6.3.3.1.4. Role of Pharmacists in France Healthcare System
      • 6.3.3.2. Pricing & Reimbursement
        • 6.3.3.2.1. Reimbursement Process
        • 6.3.3.2.2. Pricing of Pharmaceuticals
      • 6.3.3.3. Health Technology Assessment
        • 6.3.3.4. Oncology Cost of Treatment in France
        • 6.3.3.5. France Payer's Insight
        • 6.3.3.6. Features of Oncology in France
    • 6.3.4. Italy
      • 6.3.4.1. Italy Healthcare System
        • 6.3.4.1.1. Healthcare Expenditure
        • 6.3.4.1.2. Health Coverage
        • 6.3.4.1.3. Key Formularies
        • 6.3.4.1.4. Role of Pharmacists in Italy Healthcare System
      • 6.3.4.2. Pricing & Reimbursement
        • 6.3.4.2.1. Reimbursement Process
        • 6.3.4.2.2. Pricing Approval Process
      • 6.3.4.3. Health Technology Assessment
      • 6.3.4.4. Oncology Cost of Treatment in Italy
      • 6.3.4.5. Italy Payer's Insight
      • 6.3.4.6. Features of Oncology in Italy
    • 6.3.5 Spain
      • 6.3.5.1 Spain Healthcare System
        • 6.3.5.1.1. Healthcare Expenditure
        • 6.3.5.1.2. Health Coverage
        • 6.3.5.1.3. Key Formularies
        • 6.3.5.1.4. Role of Pharmacists in Spain Healthcare System
      • 6.3.5.2. Pricing & Reimbursement
        • 6.3.5.2.1. Reimbursement of Pharmaceuticals in Spain
        • 6.3.5.2.2. Pricing of Pharmaceuticals in Spain
      • 6.3.5.3. Health Technology Assessment
      • 6.3.5.4. Oncology Cost of Treatment in Spain
      • 6.3.5.5 Spain Payer Insight
      • 6.3.5.6. Features of Oncology in Spain
  • 6.4. Asia-Pacific
    • 6.4.1 Japan
      • 6.4.1.1. Japan Healthcare System
        • 6.4.1.1.1 Key Formularies
      • 6.4.1.2. Pricing & Reimbursement
      • 6.4.1.3. Health Technology Assessment
      • 6.4.1.4. Oncology Cost of Treatment in Japan
    • 6.4.2 Australia
      • 6.4.2.1 Australia Healthcare System
        • 6.4.2.1.1 Healthcare Expenditure:
        • 6.4.2.1.2 Health Coverage
        • 6.4.2.1.3 Key Formularies
        • 6.4.2.1.4 Role of Pharmacists in Australian Healthcare System
      • 6.4.2.2. Pricing & Reimbursement
        • 6.4.2.3. Health Technology Assessment
        • 6.4.2.4. Oncology Cost of Treatment in Australia
        • 6.4.2.5. Australia's Payer's Insight
        • 6.4.2.6. Features of Australian Healthcare for Oncology
  • 6.5. BRIC
    • 6.5.1. Brazil
      • 6.5.1.1. Brazilian Healthcare System
        • 6.5.1.1.2. ANVISA's Regulatory framework for biological products
      • 6.5.1.2. Brazil Pricing and Reimbursement
        • 6.5.1.2.1. Pricing Process
        • 6.5.1.2.2. Reimbursement Process
      • 6.5.1.3. Health Technology Assessment
      • 6.5.1.4. Cost of Oncology in Brazil
      • 6.5.1.5. Brazil Payer's Insight
      • 6.5.1.6. Features of Oncology in Brazil
    • 6.5.2. Russia
      • 6.5.2.1. Russia Healthcare System
        • 6.5.2.1.1. Healthcare Expenditure
      • 6.5.2.2. Pricing & Reimbursement
      • 6.5.2.3. Health Technology Assessment
      • 6.5.2.4. Cost of Oncology in Russia
      • 6.5.2.5. Russia Payer's Insight
      • 6.5.2.6. Features of Oncology in Russia
    • 6.5.3 India
      • 6.5.3.1 India Healthcare System
      • 6.5.3.2 Pricing & Reimbursement
        • 6.5.3.2.1. Pricing of Pharmaceuticals in India
        • 6.5.3.2.2. Reimbursement of Pharmaceuticals in India
      • 6.5.3.3 Cost of Oncology Treatment in India
      • 6.5.3.4 India Payer Insight
      • 6.5.3.5 Features of Oncology in India
    • 6.5.4. China
      • 6.5.4.1. China Healthcare System
        • 6.5.4.1.1. Healthcare Expenditure
        • 6.5.4.1.2. Health Insurance & Coverage in China
      • 6.5.4.2. Pricing & Reimbursement
        • 6.5.4.2.1. Pricing of Pharmaceuticals in China
        • 6.5.4.2.2. Reimbursement of Pharmaceuticals in China
      • 6.5.4.3. Health Technology Assessment (HTA)
      • 6.5.4.4. Oncology Cost of Treatment in China
      • 6.5.4.5. China Payer's Insight
      • 6.5.4.6. Features of RA in China

7. Parallel Import & Its Impact

  • 7.1. Parallel Import in Europe
  • 7.2. Parallel Import in the U.S.
  • 7.3. Economic aspects in Parallel trade

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.